ClinicalTrials.gg
RecruitingNCT06239727Updated Mar 6, 2026

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

A Phase 3 interventional study of PD-1 blocking antibody and Gemcitabine in Nasopharyngeal Carcinoma, sponsored by Sun Yat-sen University. Recruiting at 26 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
593
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University — 80 open to participants now, 107 under way, 43 of them phase 3. Nasopharyngeal Carcinoma · Sun Yat-sen University.

Planned enrollment
6th of 161
593 · median 162
Started
2024
with 20 others
Phase 3
58 of 186
26 open now
Primary completion
2027-02
later than 70 of 106 live
Registered
143rd of 186
by date

Among the 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University, this one is the 6th largest by planned enrollment of the 161 interventional ones that give a count, is one of 21 that started in 2024, is one of 58 in phase 3, reaches primary completion later than 70 of the 106 other live ones, and was the 143rd registered.

Nasopharyngeal Carcinoma

683 studies on the registry are indexed under Nasopharyngeal Carcinoma; 270 are open to participants now.

Browse Nasopharyngeal Carcinoma studies →

Open to participants now

80 of the 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University are open now, in 2 countries. Recruiting first, the newest first:

75 more — sign in →

By country, each count listing its studies:

All 80 open studies →

Where they have run

Who these studies take

Of the 186 Nasopharyngeal Carcinoma studies recruiting now, 42 (23%) set no upper age limit and 135 (73%) stop at 75 or younger; 9 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Nasopharyngeal Carcinoma by Sun Yat-sen University, or all of them as a file.
02

Study summary

This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and immunotherapy on patients' prognosis and complication compared with conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response.

Read the detailed description

The goals of this clinical trial includes: ① To confirm whether LRRFS after reduced-dose radiotherapy in combination with chemotherapy and immunotherapy is non-inferior to LRRFS after conventional-dose radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage III NPC patients screened out according to the treatment response; ② To explore the impact of reduced-dose radiotherapy on 3-year OS, 3-year PFS, 3-year DMFS, 3-year LRFS and 3-year RRFS for treatment-sensitive stage III NPC patients screened out according to the treatment response; ③ To explore the impact of reduced-dose radiotherapy on radiotherapy complications and quality of life; ④ To explore the interaction between different clinical factors and the impact of reduced-dose radiotherapy on the prognosis of patients; ⑤ To explore the biomarkers of sensitivity to chemotherapy and radiotherapy for patients with nasopharyngeal carcinoma and the underlying mechanism.

For these purposes, we plan to prospectively enroll stage III NPC patients from hospitals in China. The participants will receive 3 cycles of induction chemotherapy (GP regimen + Camrelizumab) followed by intensity-modulated radiation therapy. 2 cycles of concurrent chemotherapy will be administered during the radiotherapy. Patients' treatment response will be evaluated with MRI examination after 27 fractions of radiotherapy. If the treatment response after 27 fractions of radiotherapy is complete remission, the participants will be randomized into reduced-dose radiotherapy group and conventional-dose radiotherapy group. If the treatment response after 27 fractions of radiotherapy is not complete remission, the participants will be assigned to the unenrolled group. All the participants in the unenrolled group will receive conventional-dose radiotherapy. After the radiotherapy, all the participants will receive 9 cycles of Camrelizumab immunotherapy. Besides, all the participants in the unenrolled group will also receive metronomic adjuvant capecitabine chemotherapy for 1 year. The prognosis, complication, and quality of life will be compared between the reduced-dose radiotherapy group and the conventional-dose radiotherapy group.

03

Conditions studied

  • Nasopharyngeal Carcinoma

Keywords

  • Radiotherapy
  • Dose
  • PD-1
  • Immune Checkpoint Inhibitor
  • Capecitabine
  • Quality of Life
  • Personalised Therapy
  • Complication
  • Deintensification
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18 Years to 65 Years;
  2. performance status ≤1;
  3. Patients with newly diagnosed, confirmed nasopharyngeal carcinoma, the pathological type is non-keratinising carcinoma;
  4. Tumor staged as Stage III (T3N0 Excepted; AJCC 8th);
  5. Patients' lymph node without adverse features (no central necrosis, no muscle/skin invasion, no lymph node fusion);
  6. Normal bone marrow function: white blood cell count > 4×10\^9/L, > 90g/L, count > 100×10\^9/L;
  7. Normal liver and kidney function: total ≤ 1.5 × (ULN), and aspartate transaminase ≤ 2.5 × ULN, alkaline phosphatase ≤ 2.5 × ULN, rate ≥ 60 ml/min;
  8. Receive 3 cycles of indction chemotherapy (GP regimen + Camrelizumab);
  9. Plasma EBV DNA after the second cycle of concurrent chemotherapy: negative;
  10. Complete remission after 27 fractions of radiotherapy based on the MRI examination of the nasopharynx and neck (According to 1.1);
  11. Patients must sign and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule;
  12. Subjects with pregnancy ability must agree to use reliable measures from screening to 1 year after treatment.

Exclusion criteria

Exclusion Criteria:

  1. virus surface antigen (HBsAg) positive and Hepatitis B virus DNA > 1000 copies/ml;
  2. Anti- virus positive;
  3. Anti- (HIV) positive or diagnosed with acquired immune deficiency syndrome (AIDS);
  4. Active tuberculosis: active tuberculosis in the past 1 year should be excluded regardless with treatment, history of active tuberculosis over 1 year should be excluded except that previous regulatory anti-tuberculosis treatment is proved;
  5. Active, known or suspected disease (including but not limited to uveitis, enteritis, hepatitis, pituitary, nephritis, vasculitis, hyperthyroidism, hypothyroidism and asthma requiring bronchiectasis). Exceptions are type I diabetes mellitus, hypothyroidism requiring hormone replacement therapy, skin disorders requiring no systemic treatment (such as vitiligo, psoriasis or alopecia);
  6. Previous interstitial lung disease or pneumonia requiring oral or intravenous therapy;
  7. Chronic treatment with systemic glucocorticoid (dose equivalent to or over 10 mg prednisone per day) or any other form of therapy. Subjects who used inhaled or topical corticosteroids were eligible;
  8. Uncontrolled heart disease, for example: 1) heart failure ( level ≥ 2), 2) unstable angina, 3) myocardial infarction in past 1 year, 4) supraventricular or ventricular arrhythmia requiring treatment or intervention;
  9. Active infection requiring systemic treatment;
  10. Previous or concurrent with other malignant tumors, except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary cancer;
  11. History of radiotherapy, except for non-melanoma skin cancer located outside the target volume of radiotherapy for nasophayngeal carcinoma;
  12. Receive treatment for the local or regional disease other than that specified in the research plan;
  13. Pregnant or lactating women (pregnancy test should be considered for women with sexual life and fertility);
  14. Allergy to macromolecular protein preparations, or any component of Camrelizumab;
  15. Receiving within 30 days of the initial Camrelizumab;
  16. to MRI examination, for example: claustrophobia, allergy to MRI contrast;
  17. History of psychotropic disease, alcoholism or drug abuse, and other situation assessed by the investigators that may compromise the safety or compliance of patients, such as serious disease requiring timely treatment (including mental illness), severe laboratory abnormalities, or family-social risk factors.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
593 participants (estimated)

Study arms

  • Experimental
    Reduced-dose radiotherapy group

    All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by reduced-dose intensity-modulated radiation therapy (IMRT; 6360cGy, 30 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.

    Drug: PD-1 blocking antibody · Drug: Gemcitabine · Drug: Cisplatin (80 mg/m2) · Radiation: Reduced-dose Intensity-modulated radiotherapy · Drug: Cisplatin (100 mg/m2)

  • Active comparator
    Conventional-dose radiotherapy group

    All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles.

    Drug: PD-1 blocking antibody · Drug: Gemcitabine · Drug: Cisplatin (80 mg/m2) · Radiation: Conventional-dose Intensity-modulated radiotherapy · Drug: Cisplatin (100 mg/m2)

  • Other
    Not-Randomized population

    All participants will receive induction chemotherapy and immunotherapy (every 3 weeks × 3 cycles of gemcitabine 1000 mg/m2 day 1, 8 + cisplatin 80 mg/m2 day 1 + camrelizumab 200 mg day 1) followed by conventional-dose intensity-modulated radiation therapy (IMRT; 6996cGy, 33 fractions, 5 fractions/week, 1 fraction/day). During the radiotherapy, all the participants will receive concurrent chemotherapy (every 3 weeks × 2 cycles of cisplatin 100 mg/m2 day 1). After 3 weeks of the completion of concurrent chemoradiotherapy, adjuvant camrelizumab (200 mg per cycle) will be administrated every 3 weeks for 9 cycles. Besides, all the participants should also receive metronomic adjuvant capecitabine chemotherapy (capecitabine 650 mg/m2 p.o. BID 1 year) immediately after the completion of concurrent chemoradiotherapy.

    Drug: PD-1 blocking antibody · Drug: Gemcitabine · Drug: Cisplatin (80 mg/m2) · Radiation: Conventional-dose Intensity-modulated radiotherapy · Drug: Cisplatin (100 mg/m2) · Drug: Capecitabine

Interventions

  • DrugImmune checkpoint inhibitorsStudies of Immune checkpoint inhibitorsImmune checkpoint inhibitors pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 200 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC. 2. Adjuvant PD-1 blocking antibody: every 3 weeks × 9 cycles; 200 mg, day 1.

    Also known as: Camrelizumab

  • Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles.

    Also known as: GEM

  • DrugCisplatin (80 mg/m2)

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles.

    Also known as: DDP

  • RadiationReduced-dose Intensity-modulated radiotherapy

    1. Definitive IMRT, 30 fractions, 5 fractions/week, 1 fraction/day 2. Radiotherapy dose: pGTV: 6360cGy/30F; pCTV1: 5460cGy/30F; pCTV2: 4920cGy/30F.

    Also known as: Reduced-dose IMRT

  • RadiationConventional-dose Intensity-modulated radiotherapy

    1. Definitive IMRT, 33 fractions, 5 fractions/week, 1 fraction/day 2. Radiotherapy dose: pGTV: 6996cGy/33F; pCTV1: 6006cGy/33F; pCTV2: 5412cGy/33F.

    Also known as: Conventional-dose IMRT

  • DrugCisplatin (100 mg/m2)

    Drug page: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles

    Also known as: DDP

  • Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.

06

What researchers measure

Primary outcomes

  1. Locoregional failure-free survival (LRFFS)

    Locoregional failure-free survival is measured from day of diagnosis until local or regional recurrence.

    Time frame: 3-year

Secondary outcomes

  1. Overall survival (OS)

    Overall survival is measured from day of diagnosis until death from any cause.

    Time frame: 3 year

  2. Failure-free survival (FFS)

    Failure-free survival is measured from day of diagnosis until local recurrence, regional recurrence, distant failure, or death from any cause, whichever occurred first.

    Time frame: 3 year

  3. Distant failure-free survival (DFFS)

    Distant failure-free survival is measured from day of diagnosis until distant failure.

    Time frame: 3 year

  4. Local failure-free survival (LFFS)

    Local failure-free survival is measured from day of diagnosis until local recurrence.

    Time frame: 3 year

  5. Regional failure-free survival (RFFS)

    Regional failure-free survival is measured from day of diagnosis until regional recurrence.

    Time frame: 3 year

  6. Incidence rate of investigator-reported radiotherapy-related complications

    Time frame: Within (acute complication) / since (late complication) 90 days after the radiotherapy onset.

  7. Incidence rate of patient-reported adverse events

    Time frame: 3 year

  8. Quality of life (QoL): questionnaire

    Time frame: Regular evaluation after 30 fractions of radiotherapy.

07

Study locations

26 of 26 sites recruiting
  • Fujian Cancer Hospital
    Fuzhou, Fujian, China
    Recruiting
    • Chuan-Ben Chen · Contact
    • Chuan-Ben Chen · Principal investigator
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian, China
    Recruiting
    • San-Gang Wu · Contact
    • San-Gang Wu · Principal investigator
  • Dongguan People's Hospital
    Dongguan, Guangdong, China
    Recruiting
    • Zhi-Gang Liu · Contact
    • Zhi-Gang Liu · Principal investigator
  • The First People's Hospital of Foshan
    Foshan, Guangdong 528000, China
    Recruiting
    • Gui-Chao Liu · Contact490690@qq.com · 8618038865028
    • Gui-Chao Liu · Principal investigator
  • Sun Yat-Sen University Cancer Center
    Guangzhou, Guangdong 510060, China
    Recruiting
  • The Affiliated Panyu Central Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 511400, China
    Recruiting
    • Guo-Rong Zou · Contact
    • Guo-Rong Zou · Principal investigator
  • Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong, China
    Recruiting
    • Chuang-Zhen Chen · Contact
    • Chuang-Zhen Chen · Principal investigator
  • Affiliated Hospital of Guangdong Medical University
    Zhanjiang, Guangdong, China
    Recruiting
    • Hai-Qing Luo · Contact
    • Hai-Qing Luo · Principal investigator
  • Guangdong Nongken Central Hospital
    Zhanjiang, Guangdong, China
    Recruiting
    • Rui-Wen Huang · Contact
    • Rui-Wen Huang · Principal investigator
  • Cancer Hospital of Guangxi Medical University
    Nanning, Guangxi, China
    Recruiting
  • Cancer Hospital of Guizhou Medical University
    Guiyang, Guizhou, China
    Recruiting
  • The Second Affiliated Hospital of Hainan Medical University
    Haikou, Hainan, China
    Recruiting
    • Yue-Can Zeng · Contact
    • Yue-Can Zeng · Principal investigator
  • Hubei Province Cancer Hosiptal
    Wuhan, Hubei, China
    Recruiting
    • De-Sheng Hu, M.D. · Contacthds_005@163.com
    • De-Sheng Hu · Principal investigator
  • Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
    • Guang-Yuan Hu · Contact
    • Guang-Yuan Hu · Principal investigator
  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
    Recruiting
  • Hunan Cancer Hospital
    Changsha, Hunan 410000, China
    Recruiting
    • Ya-Qian Han · Contacthanyaqiancs@163.com
    • Ya-qian Han · Principal investigator
    • Feng Liu · Sub investigator
  • Xiangya Hospital Central South University
    Changsha, Hunan, China
    Recruiting
    • Liang-Fang Shen, MD · Contactslf1688@sina.com
    • Liang-Fang Shen · Principal investigator
  • Jiangsu Cancer Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Li Yin · Contact
    • Li Yin · Principal investigator
  • Jiangsu Provinee Hospital of Chinese Medicine
    Nanjing, Jiangsu, China
    Recruiting
    • Jing Yan · Contact
    • Jing Yan · Principal investigator
  • Jiangxi Cancer Center
    Nanchang, Jiangxi, China
    Recruiting
    • Jin-Gao Li · Contact
    • Xiao-Chang Gong · Contact
    • Jin-Gao Li · Principal investigator
    • Xiao-Chang Gong · Sub investigator
  • The First Affiliated Hospital of Xian Jiaotong University
    Xian, Shanxi, China
    Recruiting
    • Rui Liu · Contact
    • Rui Liu · Principal investigator
  • Sichuan Cancer Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Shi-Chuan Zhang · Contact
    • Shi-Chuan Zhang · Principal investigator
  • West China Hospital,Sichuan University
    Chengdu, Sichuan, China
    Recruiting
    • Nian-Yong Chen · Contact
    • Lei Liu · Contact
    • Nian-Yong Chen · Principal investigator
    • Lei Liu · Sub investigator
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China
    Recruiting
    • Xiao-Zhong Chen · Contact
    • Xiao-Zhong Chen · Principal investigator
  • Chongqing Cancer Hospital
    Chongqing, China
    Recruiting
    • Ying Wang · Contact
    • Ying Wang · Principal investigator
  • Tianjin Medical University Cancer Institute & Hospital
    Tianjin, China
    Recruiting
    • Pei-Guo Wang · Contact
    • Pei-Guo Wang · Principal investigator
08

References and documents

Publications

  • Ma BBY, Lim WT, Goh BC, Hui EP, Lo KW, Pettinger A, Foster NR, Riess JW, Agulnik M, Chang AYC, Chopra A, Kish JA, Chung CH, Adkins DR, Cullen KJ, Gitlitz BJ, Lim DW, To KF, Chan KCA, Lo YMD, King AD, Erlichman C, Yin J, Costello BA, Chan ATC. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). J Clin Oncol. 2018 May 10;36(14):1412-1418. doi: 10.1200/JCO.2017.77.0388. Epub 2018 Mar 27. PubMed 29584545 ↗
  • Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24. PubMed 28837405 ↗
  • Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, Xiong J, Li P, Zhao H, Huang Y, Zhang Y, Chen L, Zhou N, Zhao Y, Hou X, Yang Q, Zhang L. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol. 2018 Oct;19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9. Epub 2018 Sep 10. PubMed 30213452 ↗
  • Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, Yuan XL, Huang HX, Chen Y, Dai GH, Shi JH, Shen L, Yang SJ, Shu YQ, Liu YP, Wang W, Wu H, Feng H, Yao S, Xu RH. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). J Clin Oncol. 2021 Mar 1;39(7):704-712. doi: 10.1200/JCO.20.02712. Epub 2021 Jan 25. PubMed 33492986 ↗
  • Li XY, Luo DH, Guo L, Mo HY, Sun R, Guo SS, Liu LT, Yang ZC, Yang JH, Qiu F, Sun XS, Wang P, Liu Q, Li JB, Tang QN, Lin C, Yang Q, Liu SL, Liang YJ, Jia GD, Wen DX, Guo CY, Yan JJ, Zhao C, Chen QY, Tang LQ, Mai HQ. Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial. J Clin Oncol. 2022 Apr 10;40(11):1163-1173. doi: 10.1200/JCO.21.01467. Epub 2022 Jan 6. PubMed 34990291 ↗
  • Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, Huang J, Hu WH, Huang SH, Luo WJ, Liang JH, Zheng YM, Zhang F, Mao YP, Li WF, Zhou GQ, Liu X, Chen YP, Xu C, Lin L, Liu Q, Du XJ, Zhang Y, Sun Y, Ma J. Effect of Radiotherapy Alone vs Radiotherapy With Concurrent Chemoradiotherapy on Survival Without Disease Relapse in Patients With Low-risk Nasopharyngeal Carcinoma: A Randomized Clinical Trial. JAMA. 2022 Aug 23;328(8):728-736. doi: 10.1001/jama.2022.13997. PubMed 35997729 ↗
  • Tang LL, Huang CL, Zhang N, Jiang W, Wu YS, Huang SH, Mao YP, Liu Q, Li JB, Liang SQ, Qin GJ, Hu WH, Sun Y, Xie FY, Chen L, Zhou GQ, Ma J. Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial. Lancet Oncol. 2022 Apr;23(4):479-490. doi: 10.1016/S1470-2045(22)00058-4. Epub 2022 Feb 28. PubMed 35240053 ↗
  • Mao YP, Wang SX, Gao TS, Zhang N, Liang XY, Xie FY, Zhang Y, Zhou GQ, Guo R, Luo WJ, Li YJ, Liang SQ, Lin L, Li WF, Liu X, Xu C, Chen YP, Lv JW, Huang SH, Liu LZ, Li JB, Tang LL, Chen L, Sun Y, Ma J. Medial retropharyngeal nodal region sparing radiotherapy versus standard radiotherapy in patients with nasopharyngeal carcinoma: open label, non-inferiority, multicentre, randomised, phase 3 trial. BMJ. 2023 Feb 6;380:e072133. doi: 10.1136/bmj-2022-072133. PubMed 36746459 ↗
  • Guo SS, Yang JH, Sun XS, Liu LZ, Yang ZC, Liu LT, Liu SL, Li XY, Lv XF, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Sun R, Yang Q, Liang YJ, Jia GD, Zhao C, Chen QY, Tang LQ, Mai HQ. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. Eur J Cancer. 2023 Nov;194:113336. doi: 10.1016/j.ejca.2023.113336. Epub 2023 Sep 9. PubMed 37801967 ↗

Individual participant data

Plan to share: No — Complete de-identified patient data set will be submitted onto the Research Data Deposit (RDD) public platform (http://www.researchdata.org.cn) and available from the principal investigators upon reasonable request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Feb 2027, 35 months after the start.

Of 84 phase 3 interventional studies under Nasopharyngeal Carcinoma, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 82. This study's planned 35 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2024
First posted
Feb 2, 2024
StartActual
Mar 1, 2024
Primary completionEst.
Feb 20, 2027
CompletionEst.
Feb 20, 2030
Last update
Mar 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06239727
Responsible party
Jun Ma, MD (Professor, Sun Yat-sen University) — Principal investigator
First posted
Feb 2, 2024
Start date
Mar 1, 2024
Primary completion
Feb 20, 2027 (estimated)
Completion
Feb 20, 2030 (estimated)
Last update
Mar 6, 2026

Study contacts

Jun Ma
Contact
majun2@mail.sysu.edu.cn
+862087343469
Kai-Bin Yang
Contact
yangkb@sysucc.org.cn
+8613725368062
Jun Ma
principal investigator · Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion